我院他汀类药物用于降脂治疗中的不良反应185例分析
x
请在关注微信后,向客服人员索取文件
篇名: | 我院他汀类药物用于降脂治疗中的不良反应185例分析 |
TITLE: | |
摘要: | 目的:探讨他汀类药物用于降脂治疗中的不良反应(ADR)及相应干预对策。方法:选取2013年1月-2014年6月期间我院应用他汀类药物进行降脂治疗的患者2 106例作为研究对象,其中发生ADR的患者185例。通过对所有ADR患者病历及基础资料进行回顾性分析,总结影响他汀类药物产生ADR的相关高危因素,并研究其针对性干预防治对策。结果:185例发生ADR的患者中,男性106例(57.30%),女性79例(42.70%),总体发生率男性9.82%,女性7.69%,差异具有统计学意义(P<0.05);从患者年龄角度分析,>50岁是他汀类药物ADR发生的集中区间,其中51~60岁(63例,34.05%)、61~70岁(56例,41.48%)与其他年龄层次ADR发生率比较,差异具有统计学意义(P<0.05);ADR类型以消化系统反应、肝毒性及神经毒性反应为主,与其他类型比较,差异具有统计学意义(P<0.05);辛伐他汀、阿托伐他汀是导致ADR发生的主要因素,与其他种类药物ADR发生率比较,差异具有统计学意义(P<0.05)。结论:性别、年龄及具体药物品种所致ADR发生率有差异。临床在应用他汀类药物进行降脂治疗时应强化掌握患者降脂的适应证,谨慎选择药物治疗,以减轻药物毒性,降低ADR发生率,提高临床治疗效果。 |
ABSTRACT: | OBJECTIVE: To investigate statin-induced ADR in lipid-lowering therapy and the corresponding intervention strategies. METHODS: During Jan. 2013 to Jun. 2014, 2 106 patients receiving statin therapy for lowering lipid in our hospital were selected as subjects, involving 185 patients in ADR cases. Through medical records and basic data of all ADR patients were analyzed retrospectively, and the related risk factors were summarized and its targeted intervention countermeasures were studied. RESULTS: Among 185 cases of patients with ADR, there were 106 male patients (57.30%) and 79 female patients (42.70%), with statistical significance (P<0.05); from the angle of patient’s age, over 50 years old was concentrated interval of statins-induced ADR, of which there were statistical significances in the incidence of ADR between 51-60 years old (63 cases, 34.05%), 61-70 years old (56 cases, 41.48%) and other age groups (P<0.05); according to ADR types, main clinical manifestations were digestive system reactions, liver toxicity and neurotoxicity reaction, with statistical significance compared with other types (P<0.05); simvastatin and atorvastatin were the main factors leading ADR, there was statistical significance in the incidence of ADR compared with other drug types (P<0.05). CONCLUSIONS: This study indicates that the incidence of ADR are different among different gender, age and types of specific drugs. Lipid-lowering indications should be further mastered when statins is used for lipid-lowering therapy; drugs are selected carefully so as to relieve drug toxicity, reduce the incidence of ADR and improve clinical therapeutic effect. |
期刊: | 2016年第27卷第2期 |
作者: | 赵晓玲,王明 |
AUTHORS: | ZHAO Xiaoling,WANG Ming |
关键字: | 他汀类药物;降脂;不良反应;干预对策 |
KEYWORDS: | Statins; Lipid-lowering; ADR; Intervention countermeasures |
阅读数: | 274 次 |
本月下载数: | 6 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!